A 28-year-old Indian man with a family history of thalassemia major presents with severe hemolytic anemia (Hb 6.2 g/dL). Genetic sequencing reveals a homozygous mutation in the β-globin gene: a G→A substitution at the first nucleotide of the intron 1 splice donor site (position +1 of IVS1). RNA analysis of reticulocytes shows that β-globin mRNA is nearly absent, although some aberrant transcripts of variable length are detected. Which molecular consequence of this splice site mutation best explains the severe reduction in normal β-globin mRNA?

Explanation

## Splice Site Anatomy **Key Point:** The splice donor site (5′ splice site) at the intron–exon boundary has a highly conserved consensus sequence: **GU** at positions +1 and +2 of the intron. The mutation G→A at position +1 destroys this critical dinucleotide. ## Consequence: Intron Retention **High-Yield:** When the canonical donor site is mutated: 1. The spliceosome cannot recognize the normal splice donor site. 2. Intron 1 is **retained** in the mature mRNA. 3. The retained intron contains **in-frame stop codons** (UAG, UGA, UAA). 4. Translation terminates prematurely, producing a truncated, non-functional protein. 5. The mRNA with premature termination codons (PTCs) is recognized by **nonsense-mediated decay (NMD)** and degraded. **Mnemonic:** **SPLICER** — **S**plice site mutation → **P**remature stop codon → **L**oss of mRNA → **I**ntron **C**annot be **E**xcised → **R**apid degradation. ## Why This Is Thalassemia Major **Clinical Pearl:** In β-thalassemia major, homozygous mutations that severely reduce β-globin mRNA (like this IVS1 splice donor mutation) result in: - Near-complete absence of β-globin chains. - Severe imbalance of α:β globin chain ratio. - Precipitation of excess α-globin chains → hemolysis, ineffective erythropoiesis. - Severe anemia requiring regular transfusions. This is one of the most common β-thalassemia mutations in Mediterranean and Middle Eastern populations. ## Molecular Mechanism Flowchart ```mermaid flowchart TD A["G→A mutation at IVS1 +1"]:::outcome --> B["Canonical splice donor GU disrupted"]:::outcome B --> C{"Can spliceosome recognize site?"}:::decision C -->|No| D["Intron 1 retained in pre-mRNA"]:::action D --> E["Intron contains stop codons"]:::outcome E --> F["Premature termination codon in mRNA"]:::outcome F --> G["NMD pathway activated"]:::action G --> H["mRNA degraded"]:::urgent H --> I["Severe β-globin deficiency"]:::urgent I --> J["Thalassemia major phenotype"]:::outcome ``` ## Comparison: Splice Site Mutations vs. Other β-Globin Mutations | Mutation Type | Location | Effect on mRNA | Effect on Protein | Severity | |---------------|----------|----------------|-------------------|----------| | **Splice donor site** | IVS1 +1 | Intron retention → NMD → absent | None (mRNA degraded) | **Thalassemia major** | | **Splice acceptor site** | IVS1 -2 | Intron retention or exon skipping | Truncated or absent | **Thalassemia major** | | **Nonsense mutation** | Exon 2 | Normal splicing, normal mRNA | Premature stop → truncated protein | Thalassemia major or intermediate | | **Missense mutation** | Exon 1 | Normal splicing, normal mRNA | Amino acid substitution (e.g., Glu6Val = HbS) | Sickle cell disease or mild | | **Promoter mutation** | 5′ UTR | Reduced transcription | Reduced protein | Thalassemia trait or intermediate | **Tip:** Splice site mutations are among the most severe β-globin mutations because they eliminate the mRNA entirely via NMD, not just reduce protein function.